Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinom
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(153)
•••
Comment by Maxcitracon Dec 23, 2024 12:11pm
207 Views
Post# 36375200

RE:RE:BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinom

RE:RE:BCG-Unresponsive Non-Muscle Invasive Bladder Cancer CarcinomLegit62, Theralase not saying anything about BTD, could be interpreted as a positive sign for BTD approval in 2025.
The reason being, when Theralase will announce BTD appoval in 2025, Theralase could have to do a Trading Stop, because of the possibility of a big increase in the SP value.
At this point in time,Theralase can't take any chance of releasing any news about the BTD situation
that could jeopardize the future Trading Stop news release of the BTD approval itself.

I can't believe, all the beautiful Ruvidar data 2024 has brought us, and I can't wait to see where Theralase will go in 2025.
Best Maxitrac.

Legit62 wrote: Very interesting, no message of BTD, what the heck is up with that??? Did the FDA throw us under the bus?? Or is Theralase not saying anything at this point in time???? Was hoping we had news shortly


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities